Illumina Ordered to Divest Grail by Federal Trade Commission (1)

The Federal Trade Commission issued an Opinion and Order requiring DNA sequencing provider, Illumina, to divest GRAIL.

• Deal would stifle competition and innovation in the US market for cancer tests: FTC
• Opinion reverses an Administrative Law Judge’s Initial Decision that dismissed the antitrust charges in a complaint brought by FTC staff
• Commission found that the acquisition would diminish innovation in the US market for MCED tests while increasing prices and decreasing choice and quality of tests: statement

NOTE: Icahn Blasts Illumina’s Board Over Grail Purchase (1)

(Updates with details)

To contact the reporter on this story:
Georgi Azar in ...